Salvatore Siena
Impact in
- Oncology top 0.01%
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cancer Research top 0.05%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 386
- Colorectal Cancer Treatments and Studies 256
- HER2/EGFR in Cancer Research 66
- Cancer Treatment and Pharmacology 47
-
- Lung Cancer Treatments and Mutations 127
- Gastric Cancer Management and Outcomes 86
- Co-authors
- Alberto Bardelli (78 shared papers)Andrea Sartore‐Bianchi (140 shared papers)Eric Van Cutsem (64 shared papers)Yves Humblet (34 shared papers)Federica Di Nicolantonio (32 shared papers)Marco Bregni (84 shared papers)Silvia Marsoni (47 shared papers)Marc Peeters (43 shared papers)
- Journals
- Journal of Clinical Oncology (131 papers)Annals of Oncology (94 papers)European Journal of Cancer (20 papers)Blood (16 papers)ESMO Open (14 papers)
- Partner nations
- ItalyUnited StatesSpain
In The Last Decade
Salvatore Siena
529 papers receiving 38.7k citations
Salvatore Siena's Hit Papers
Peers
Comparison fields: 5 of 153
- Oncology 23.8k
- Cancer Research 6.1k
- Hepatology 2.8k
- Pathology and Forensic Medicine 6.4k
- Pulmonary and Respiratory Medicine 9.2k
Countries citing papers authored by Salvatore Siena
This map shows the geographic impact of Salvatore Siena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Salvatore Siena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Salvatore Siena more than expected).
Fields of papers citing papers by Salvatore Siena
This network shows the impact of papers produced by Salvatore Siena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Salvatore Siena. The network helps show where Salvatore Siena may publish in the future.
Co-authors
The 25 scholars most cited alongside Salvatore Siena, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 542 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer Hit paper breakdown → | 2004 | 4041 |
| 2 | Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 2515 |
| 3 | Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2012 | 2139 |
| 4 | Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Hit paper breakdown → | 2007 | 1588 |
| 5 | Integrating liquid biopsies into the management of cancer Hit paper breakdown → | 2017 | 1465 |
| 6 | Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study Hit paper breakdown → | 2010 | 1393 |
| 7 | Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 1315 |
| 8 | Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2014 | 1205 |
| 9 | Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Hit paper breakdown → | 2005 | 796 |
| 10 | Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies Hit paper breakdown → | 2007 | 691 |
| 11 | GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION Hit paper breakdown → | 1989 | 625 |
| 12 | PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies Hit paper breakdown → | 2009 | 622 |
| 13 | Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab Hit paper breakdown → | 2010 | 596 |
| 14 | Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer Hit paper breakdown → | 2010 | 558 |
| 15 | nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial Hit paper breakdown → | 2015 | 523 |
| 16 | Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial Hit paper breakdown → | 2023 | 514 |
| 17 | 1989 | 456 | |
| 18 | 1991 | 452 | |
| 19 | Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials Hit paper breakdown → | 2012 | 446 |
| 20 | NTRK gene fusions as novel targets of cancer therapy across multiple tumour types Hit paper breakdown → | 2016 | 442 |
About Salvatore Siena
Salvatore Siena is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Pathology and Forensic Medicine and Hematology, having authored 542 papers that have together received 39.8k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (256 papers), Lung Cancer Treatments and Mutations (127 papers), Cancer Genomics and Diagnostics (87 papers), Gastric Cancer Management and Outcomes (86 papers), HER2/EGFR in Cancer Research (66 papers), Genetic factors in colorectal cancer (48 papers), Cancer Treatment and Pharmacology (47 papers) and Hematopoietic Stem Cell Transplantation (45 papers). The work is most often cited by research in Oncology (23.8k citations), Cancer Research (6.1k citations), Hepatology (2.8k citations), Pathology and Forensic Medicine (6.4k citations) and Pulmonary and Respiratory Medicine (9.2k citations). Salvatore Siena has collaborated with scholars based in Italy, United States and Spain. Frequent co-authors include Alberto Bardelli, Andrea Sartore‐Bianchi, Eric Van Cutsem, Yves Humblet, Federica Di Nicolantonio, Marco Bregni, Silvia Marsoni, Marc Peeters, David Cunningham and Michael Wolf. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Blood and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.